Breaking News Headlines Today

News from Express Pharma

Your destination for news from Express Pharma. See how Express Pharma’s media bias impacts the breaking news stories of today.

We’ve aggregated 255 of Express Pharma’s headlines and news stories over the past 3 months.

Ground News rates Express Pharma’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Express Pharma’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Express Pharma

Where is Express Pharma located?Express Pharma's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market - Trinity Biotech (NASDAQ:TRIB)

100% Center coverage: 2 sources

WILSONVILLE, Ore. and DUBLIN, July 24, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today unveiled its new flagship product, CGM+, a next-generation wearable biosensor platform designed for the $260 billion AI wearables market. Now in the later stages of device development, CGM+ is Trinity's new A…See the Story

806 Applications Approved so Far Under PLI Schemes: Govt in Lok Sabha

New Delhi: The government on Tuesday said as many as 806 applications have been approved under the Production Linked Incentive (PLI) schemes across 14 sectors as on date. The schemes for 14 key sectors including telecom, electronics, pharma, textiles and auto were announced with an outlay of Rs 1.97 lakh crore to enhance India’s manufacturing capabilities and exports. It was announced in 2021. “As on date, 806 applications have been approved und…Innovation · India See the Story

Why India's B.Pharm graduates need a standardised National Exit Exam - Express Pharma

India’s pharmaceutical industry has achieved international recognition as the “Pharmacy of the World,” particularly for its imperative role in supplying vaccines, essential medicines, and medical supplies during the COVID-19 pandemic and beyond. The sector has showcased its innovative capabilities and established itself as a crucial global pharmaceutical value chain member. The country’s pharmaceutical support and export extends to both the deve…Pharma · India Read Article

Exclusive interview with Dilip Singh Rathod, President India Business, JB Pharma - Express Pharma

In this interview, Dilip Singh Rathod, President: India Business, JB Pharma, offers insights into the company’s India growth strategy and its expanding role in chronic disease management The post Exclusive interview with Dilip Singh Rathod, President India Business, JB Pharma appeared first on Express Pharma.Pharma · India Read Article

Diagnosed prevalent cases of HER2- breast cancer across 8MM set to reach 4.12 mn in 2034 - Express Pharma

The burden of five-year diagnosed prevalent cases of HER2-Negative (HER2-) breast cancer is expected to increase at an annual growth rate (AGR) of 1.42 per cent from around 3.61 million in 2024 to 4.12 million in 2034 across the eight major markets (8MM*), forecasts GlobalData. GlobalData’s latest report, “HER2-Negative Breast Cancer: Epidemiology Forecast to 2034,” reveals that the increase is partly attributed to an increased incidence of HER2…Breast Cancer · United States Read Article

India overtakes Iran in clinical trial initiations outside North America and Europe in Q2 2025 - Express Pharma

China maintains its place as the most popular country for clinical trials outside North America and Europe for Q2 2025. However, India knocked Iran out of second place with the most clinical trials initiated in the rest of the world (ROW), according to a report by GlobalData. GlobalData’s latest report, “Q2 2025 Clinical Trials: CRO, Sponsor & Country Winners,” reveals that Iran’s clinical trials have been affected, with 348 trials initiated in …India · India Read Article

Baxdrostat met primary, secondary endpoints in BaxHTN Phase III trial in patients with treatment-resistant hypertension - Express Pharma

Positive high-level results from the BaxHTN Phase III trial showed that baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or treatment-resistant hypertension received baxdrostat or placebo on top of standard of care. Bax…London, England · London Read Article

Kilitch Drugs to raise around ₹50 crore via rights issue at Rs. 375 per share - Express Pharma

Kilitch Drugs, a pharmaceutical company specialising in the manufacturing and distribution of high-quality Parenteral, Injectables, Oral Solids, and Effervescent formulations, has received approval from the board to raise around ₹49.92 crore via a rights issue. In its board meeting, the Board of Directors finalised the Rights Issue of 13,98,463 fully paid-up equity shares of face value ₹10/- each at an issue price of ₹357/- per share (including …Pharma · Pen Read Article

News from Express Pharma

News from Express Pharma

Information about Express Pharma

Media Bias Ratings

Factuality

Ownership

Top Express Pharma News

Zydus Lifesciences Secures Tentative FDA Nod for Generic Cancer Drug

Zydus Lifesciences Secures Tentative FDA Nod for Generic Cancer Drug

Pfizer, Chinese Biotech Firm 3SBio Complete Licensing Deal for Cancer Drug

Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market - Trinity Biotech (NASDAQ:TRIB)

806 Applications Approved so Far Under PLI Schemes: Govt in Lok Sabha

Why India's B.Pharm graduates need a standardised National Exit Exam - Express Pharma

Exclusive interview with Dilip Singh Rathod, President India Business, JB Pharma - Express Pharma

Diagnosed prevalent cases of HER2- breast cancer across 8MM set to reach 4.12 mn in 2034 - Express Pharma

India overtakes Iran in clinical trial initiations outside North America and Europe in Q2 2025 - Express Pharma

Baxdrostat met primary, secondary endpoints in BaxHTN Phase III trial in patients with treatment-resistant hypertension - Express Pharma

Kilitch Drugs to raise around ₹50 crore via rights issue at Rs. 375 per share - Express Pharma

Similar News Topics

Topics Most Covered by Express Pharma

Sources Covering Similar Topics

Breaking News Topics Related to Express Pharma

Information about Express Pharma

Media Bias Ratings

Factuality

Ownership

Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market - Trinity Biotech (NASDAQ:TRIB)

806 Applications Approved so Far Under PLI Schemes: Govt in Lok Sabha

Why India's B.Pharm graduates need a standardised National Exit Exam - Express Pharma

Exclusive interview with Dilip Singh Rathod, President India Business, JB Pharma - Express Pharma

Diagnosed prevalent cases of HER2- breast cancer across 8MM set to reach 4.12 mn in 2034 - Express Pharma

India overtakes Iran in clinical trial initiations outside North America and Europe in Q2 2025 - Express Pharma

Baxdrostat met primary, secondary endpoints in BaxHTN Phase III trial in patients with treatment-resistant hypertension - Express Pharma

Kilitch Drugs to raise around ₹50 crore via rights issue at Rs. 375 per share - Express Pharma